Ignite Creation Date:
2024-05-06 @ 12:10 AM
Last Modification Date:
2024-10-26 @ 10:45 AM
Study NCT ID:
NCT01508910
Status:
COMPLETED
Last Update Posted:
2018-12-19
First Post:
2012-01-10
Brief Title:
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34 Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
Sponsor:
Lisata Therapeutics Inc
Organization:
Lisata Therapeutics Inc
Study Overview
Official Title:
A Prospective Randomized Double-blinded Active-control and Unblinded Standard of Care SOC Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34 Cells Auto-CD34 Cells for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RENEW
Brief Summary:
The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34 cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RENEW Study | OTHER | Caladrius Biosciences Inc | None |